KELOWNA, BRITISH COLUMBIA -- (MARKET WIRE) -- October 02, 2006 -- Sernova Corp. ("Sernova") (TSX VENTURE: SVA) notes with interest the positive results of a recent international trial of islet transplantation for the reversal of diabetes. Published last week in the New England Journal of Medicine and subsequently reported by many media outlets, this study of the "Edmonton Protocol" also revealed the failure of anti-rejection drugs to adequately protect the transplanted, insulin producing islets.
